MUC16 and uterine corpus sarcoma: Confirming the limitations of this biomarker, another study conducted in 2009 on a large cohort of 2382 patients with leiomyoma and 26 with uterine sarcoma concluded that CA125 has no predictive value in differential diagnosis [17].